trending Market Intelligence /marketintelligence/en/news-insights/trending/HjUZG9jye3-Mh1IUBei4SA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pfizer's investigational treatment shows anti-tumor activity in study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Pfizer's investigational treatment shows anti-tumor activity in study

Pfizer Inc.'s investigational drug talazoparib showed anti-tumor activity in patients with germline or inherited BRCA1/2-positive advanced breast cancer in a phase 2 trial.

The study investigated the clinical efficacy and safety of talazoparib in 83 heavily pretreated gBRCA+ advanced breast cancer patients, with objective response rate, or ORR, by independent radiology review as the primary endpoint.

A 21% ORR was observed in a group of 49 patients who previously responded to platinum-based chemotherapy and developed disease progression, while a 37% ORR was logged in a group of 35 patients who developed disease progression following at least three lines of non-platinum-based therapy, Pfizer said in a news release.

Talazoparib is also being investigated in a fully enrolled phase 3 trial in advanced gBRCA+ breast cancer.

BRCA1 and BRCA2 are human genes producing proteins for DNA repair. An alteration or mutation of either of the genes could result in a stunted progression of DNA repair, resulting in certain types of cancer.